Novel Therapy Found Effective for Polycythemia Vera in Phase 3 Trial

In an ongoing phase 3 trial, rusfertide (Takeda/Protagonist Therapeutics), a first-in-class hepcidin mimetic, reduced symptoms and the need for phlebotomy in patients with polycythemia vera.